Holen Sie sich die Stockscreener-App
4.37
0.68%
-0.03
Handel nachbörslich:
4.37
Schlusskurs vom Vortag:
$4.40
Offen:
$4.46
24-Stunden-Volumen:
329.88K
Relative Volume:
1.20
Marktkapitalisierung:
$60.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-56.20M
KGV:
-1.2241
EPS:
-3.57
Netto-Cashflow:
$-39.97M
1W Leistung:
-17.70%
1M Leistung:
-33.18%
6M Leistung:
-27.53%
1J Leistung:
-59.35%
1-Tages-Spanne:
$4.30
$4.53
1-Wochen-Bereich:
$4.30
$5.3565
52-Wochen-Spanne:
$4.30
$22.49
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Vergleichen Sie ANVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
4.37 | 60.29M | 0 | -56.20M | -39.97M | -6.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Bio stock hits 52-week low at $4.52 amid market challenges - Investing.com Australia
When (ANVS) Moves Investors should Listen - Stock Traders Daily
Annovis Bio (NYSE: ANVS) Eyes Clear Path Forward For Buntanetap - Barchart
Annovis Bio, Inc. (NYSE:ANVS) Short Interest Update - MarketBeat
Royal Bank of Canada (RY-N) QuotePress Release - The Globe and Mail
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Annovis Bio (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Investor Webcast - Barchart
Annovis Bio, Inc. Appoints William Fricker to Serve as Chief Financial Officer on an Interim Basis - Marketscreener.com
Annovis Bio Announces Investor Webcast to Share Key Updates - MSN
Annovis Bio Advances Alzheimer’s and Parkinson’s Drug Trials - TipRanks
Form 424B5 Annovis Bio, Inc. - StreetInsider.com
Annovis Bio appoints interim CFO By Investing.com - Investing.com Nigeria
Annovis Bio appoints interim CFO - Investing.com
Annovis Bio Appoints William Fricker as Interim CFO - TipRanks
(ANVS) On The My Stocks Page - Stock Traders Daily
Annovis Bio (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace - Barchart
We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate - Simply Wall St
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace - GlobeNewswire
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s - The Bakersfield Californian
Annovis Bio (NYSE: ANVS) to Present Recent Achievements, Strategic Outlook During Investor Webcast - Barchart
Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace - PR Newswire
/C O R R E C T I O N -- Today's Marketplace/ - Quantisnow
Down Syndrome Market expected to rise | Companies- Eisai, AC Immune, Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, Annovis Bio, AelisFarma, Kinopharma, NeuroNascent, Pharmasum Thera - Barchart
Annovis Bio (NYSE: ANVS) Schedules Investor Webcast to Share Clinical and Strategic Updates - Barchart
Annovis to Host Year-End Investor Webcast on December 11, 2024 - The Manila Times
Brokerages Set Annovis Bio, Inc. (NYSE:ANVS) Target Price at $32.17 - MarketBeat
Annovis Bio (NYSE: ANVS) Paving The Way For NDA Submission - Barchart
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies - MSN
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates - MSN
When the Price of (ANVS) Talks, People Listen - Stock Traders Daily
Annovis Bio (NYSE: ANVS) Concludes Q3 with Milestones, FDA-Cleared Phase 3 Program for Alzheimer’s - Barchart
Q4 Earnings Forecast for Annovis Bio Issued By HC Wainwright - MarketBeat
Annovis Bio (NYSE: ANVS) CEO To Showcase Buntanetap’s Dual Benefits At NIA Workshop - Barchart
Veravas and Phanes Biotech Collaborate to Innovate Alzheimer’s Disease Testing - MyChesCo
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - GlobeNewswire
Annovis Bio (NYSE: ANVS) Advances Alzheimer’s Phase 3 Trials with Strong FDA Support, Financial Backing - Barchart
Annovis Bio (NYSE:ANVS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Annovis sees cash runway for Phase 3 preparatory studies, entering AD study - Nasdaq
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely? - Yahoo Finance
Annovis Bio Inc (ANVS) Quarterly 10-Q Report - Quartzy
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist - citybiz
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):